Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced intensity HSCT for severe osteopetrosis
NCT00638820Phase 2Terminated
- Sponsor
- Masonic Cancer Center
- Start
- Sep 2007
- Primary completion
- May 2008
- Modality
- Monoclonal Antibodies, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of clofarabine, busulfan and alemtuzumab in osteopetrosis, sponsored by Masonic Cancer Center. Primary endpoint: Number of Patients Achieving Donor Cell Engraftment at 100 days. Started Sep 2007; status: terminated.
02
Drugs
clofarabinebusulfanalemtuzumab
03
Conditions
osteopetrosis
Beyond the preview
Go deeper on NCT00638820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00638820.